Search | Clinical Trials Finder

Conditions: Measles, Mumps, Rubella, Varicella
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 16 Months
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: YASMIN, GSK2248761, Placebo; Drug · Other
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: HIV Infections
Interventions: Ethinyl estradiol/levonorgestrel, Medroxyprogesterone acetate; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 16 Years to 35 Years · Female only
Enrollment: 6,360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Community-acquired Pneumonia
Interventions: Omadacycline; Drug
Lead sponsor: Paratek Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 13
States / cities: Birmingham, Alabama • San Diego, California • Clearwater, Florida + 7 more

Conditions: Covid19
Interventions: Colgate Total Clean Mint, Tom's Botanically Bright Peppermint; Drug
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
Interventions: Dasatinib, Methotrexate, Prednisone, Rituximab, Venetoclax, Blinatumomab, Bone Marrow Aspiration and Biopsy, Lumbar Puncture, Biospecimen Collection; Drug · Biological · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: HIV Infections, Stomatitis, Aphthous
Interventions: Thalidomide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 18 more

Conditions: Cancer
Interventions: entinostat; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 3
States / cities: Bethesda, Maryland

Conditions: Urologic Injuries, Urologic Diseases, Bladder Infection, Urinary Tract Infections, Mucosal Inflammation, Mucosal Infection, Bladder Injury, Catheter-Related Infections, Catheter Complications, Catheter; Infection (Indwelling Catheter), Pelvic Floor Disorders, Urinary Incontinence
Interventions: Cystosure Urinary Access System, Foley Catheter; Device
Lead sponsor: The Pelvic Floor Institute; Other
Eligibility: 21 Years to 70 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Cancer
Interventions: Fentanyl sublingual spray, Placebo; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Chandler, Arizona

Conditions: Gonorrhoea
Interventions: AZD0914, Ceftriaxone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Birmingham, Alabama • Indianapolis, Indiana • New Orleans, Louisiana + 2 more

Conditions: Herpes Simplex
Interventions: valacyclovir hydrochloride, placebo, valacyclovir plus aspirin; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 20 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: New Orleans, Louisiana

Conditions: Cancer
Interventions: itraconazole, voriconazole; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 12 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Shigellosis
Interventions: Vaccine: 2.6±0.8 x 10^8 vp/mL, 1 dose, Vaccine: 2.6±0.8 x 10^9 vp/mL, 3 doses, Vaccine: 2.6±0.8 x 10^10 vp/mL, 3 doses, Vaccine: 2.6±0.8 x 10^11 vp/mL, 3 doses, Placebo: 1-3 doses; Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 45 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Bacterial Infections, Skin Structures and Soft Tissue Infections
Interventions: Omadacycline, Linezolid; Drug
Lead sponsor: Paratek Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 735 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 50
States / cities: Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 36 more

Conditions: Risk Reduction
Interventions: Vivotif Typhoid Oral Vaccine; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cytomegalovirus Infections
Interventions: valganciclovir, Placebo; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV Infections, Pregnancy
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 10
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 5 more

Conditions: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions: Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Detroit, Michigan • St Louis, Missouri • Indiana, Pennsylvania

Conditions: Dental Caries, Gingivitis
Interventions: oral health assessment, Questionnaires, Clinical Exam, Microbiological sampling, Monitoring Adherence, Varnish application, Consent, Educational Program; Other
Lead sponsor: Leonardo Marchini; Other
Eligibility: 21 Years to 120 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Caries, Tooth Decay, Cavities, Gingivitis
Interventions: Attack of the S. Mutans, Follow-up, SnowWorld; Other
Lead sponsor: University of Washington; Other
Eligibility: 8 Years to 12 Years
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Sulfamethoxazole-Trimethoprim, Leucovorin calcium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 6
States / cities: San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 3 more

Conditions: Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Neutropenia, Sarcoma
Interventions: voriconazole; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 11 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 7
States / cities: Orange, California • San Diego, California • Bethesda, Maryland + 4 more

Conditions: Rubella, Measles, Mumps
Interventions: Priorix, M-M-R II, Varivax, Havrix, Prevnar 13; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 5,016 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 62
States / cities: Dothan, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 56 more

Search by objective public record fields.

Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines

A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.

Hormonal Birth Control and the Risk of Acquiring HIV

Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia

Measurement of Viral Load Reduction in the Oral Cavity After a Regimental Use of OC Toothpaste Products

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Bladder Morphology Using 2 Different Catheter Designs

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea

30-Day Trial of Oral Valtrex or Valtrex Plus Aspirin on Shedding of HSV DNA in Tears and Saliva of Volunteers

Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults

Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI

Blood Donor CVD 5000

Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation

A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

Oral Hygiene Intervention Pilot Study

Improving Oral Health With Serious Games

Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age